###begin article-title 0
NF-kappa B genes have a major role in Inflammatory Breast Cancer
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
IBC (Inflammatory Breast cancer) is a rare form of breast cancer with a particular phenotype. New molecular targets are needed to improve the treatment of this rapidly fatal disease. Given the role of NF-kappaB-related genes in cell proliferation, invasiveness, angiogenesis and inflammation, we postulated that they might be deregulated in IBC.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
We measured the mRNA expression levels of 60 NF-kappaB-related genes by using real-time quantitative RT-PCR in a well-defined series of 35 IBCs, by comparison with 22 stage IIB and III non inflammatory breast cancers. Twenty-four distant metastases of breast cancer served as "poor prognosis" breast tumor controls.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 157 162 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKB1</italic>
###xml 164 168 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RELA</italic>
###xml 170 175 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBKG</italic>
###xml 177 183 169 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIB</italic>
###xml 185 190 177 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKB2</italic>
###xml 192 195 184 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">REL</italic>
###xml 197 201 189 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHUK</italic>
###xml 221 226 213 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCL1L</italic>
###xml 228 239 220 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFAIP3/A20</italic>
###xml 241 248 233 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GADD45B</italic>
###xml 250 255 242 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FASLG</italic>
###xml 257 262 249 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCL1S</italic>
###xml 264 269 256 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IER3L</italic>
###xml 271 288 263 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFRSF10B/TRAILR2</italic>
###xml 314 318 306 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD40</italic>
###xml 320 324 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD48</italic>
###xml 326 339 318 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFSF11/RANKL</italic>
###xml 341 355 333 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFRSF11A/RANK</italic>
###xml 357 367 349 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCL2/MCP-1</italic>
###xml 369 375 361 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD40LG</italic>
###xml 377 381 369 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL15</italic>
###xml 383 387 375 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GBP1</italic>
###xml 411 416 403 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 418 423 410 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND3</italic>
###xml 425 430 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF1R</italic>
###xml 432 436 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF1</italic>
###xml 438 442 430 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD2</italic>
###xml 468 474 460 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL12</italic>
###xml 476 480 468 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SELE</italic>
###xml 482 485 474 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNC</italic>
###xml 487 492 479 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VCAM1</italic>
###xml 494 499 486 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ICAM1</italic>
###xml 501 509 493 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLAU/UPA</italic>
###xml 534 544 526 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGS2/COX2</italic>
###xml 546 556 538 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL1/GRO1</italic>
###xml 587 598 579 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGS2/COX2 </italic>
###xml 602 612 594 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL1/GRO1</italic>
###xml 755 759 747 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL8 </italic>
###xml 763 768 755 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VEGF </italic>
###xml 723 730 <span type="species:ncbi:9606">patient</span>
Thirty-five (58%) of the 60 NF-kappaB-related genes were significantly upregulated in IBC compared with non IBC. The upregulated genes were NF-kappaB genes (NFKB1, RELA, IKBKG, NFKBIB, NFKB2, REL, CHUK), apoptosis genes (MCL1L, TNFAIP3/A20, GADD45B, FASLG, MCL1S, IER3L, TNFRSF10B/TRAILR2), immune response genes (CD40, CD48, TNFSF11/RANKL, TNFRSF11A/RANK, CCL2/MCP-1, CD40LG, IL15, GBP1), proliferation genes (CCND2, CCND3, CSF1R, CSF1, SOD2), tumor-promoting genes (CXCL12, SELE, TNC, VCAM1, ICAM1, PLAU/UPA) or angiogenesis genes (PTGS2/COX2, CXCL1/GRO1). Only two of these 35 genes (PTGS2/COX2 and CXCL1/GRO1)were also upregulated in breast cancer metastases. We identified a five-gene molecular signature that matched patient outcomes, consisting of IL8 and VEGF plus three NF-kappaB-unrelated genes that we had previously identified as prognostic markers in the same series of IBC.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
The NF-kappaB pathway appears to play a major role in IBC, possibly contributing to the unusual phenotype and aggressiveness of this form of breast cancer. Some upregulated NF-kappaB-related genes might serve as novel therapeutic targets in IBC.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 324 325 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 459 466 <span type="species:ncbi:9606">patient</span>
The main features distinguishing IBC (Inflammatory Breast Cancer) from other forms of primary breast cancer are a unique phenotype, which includes rapidly progressive breast inflammation, and an extreme tendency to metastasize. The three-year survival rate is about 40%, compared with 85% in non inflammatory breast cancer [1]. The molecular mechanisms underlying these characteristics are largely unknown, but their identification could help with diagnosis, patient stratification and drug development.
###end p 11
###begin p 12
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TP53 </italic>
###xml 132 141 132 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HER2/neu </italic>
###xml 156 157 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 162 171 162 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 175 183 175 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 207 211 207 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RhoC</italic>
###xml 213 217 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUC1</italic>
###xml 219 230 219 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E-cadherin </italic>
###xml 234 245 234 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LIBC/WISP3 </italic>
###xml 343 344 343 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 325 330 <span type="species:ncbi:9606">human</span>
We and others have described several molecular alterations in IBC, such as frequent hormone receptor negativity, TP53 mutations and HER2/neu amplification [2-5]. In vitro and in vivo studies have implicated RhoC, MUC1, E-cadherin and LIBC/WISP3 in the pathogenesis of IBC. The expression of some of these genes is altered in human IBC tumors [6]. However, none of these genetic alterations is specific to the particular phenotype of IBC.
###end p 12
###begin p 13
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 325 326 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 434 435 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 782 784 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 968 970 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1160 1162 1140 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
The advent of novel analytical methods such as DNA microarrays has helped to identify molecular signatures for various malignancies. In non inflammatory breast cancer, DNA microarray-based studies have distinguished tumor subclasses with distinct prognoses [7,8]. Few DNA microarray-based studies have been performed in IBC [9-11]. One such study identified a set of 109 genes whose expression discriminated 37 IBCs from 44 non IBCs [9]. These 109 genes, some of which were NF-kappaB-related, were mainly associated with signal transduction, cell motility, invasion, angiogenesis and local inflammatory processes. Another genome-wide expression profiling study comparing 16 IBCs with 18 non stage-matched non IBCs identified a large number of overexpressed NF-kappaB-related genes [10]. Using real-time RT-PCR, immunohistochemistry and NF-kappaB-DNA-binding assays, the same authors recently confirmed the contribution of some of these NF-kappaB-related genes in IBC [12]. In a previous study of IBC, in which we analyzed the expression of 538 cancer genes by using real-time RT-PCR, we also observed abnormal expression of several NF-kappaB-associated genes [13].
###end p 13
###begin p 14
###xml 209 211 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 212 214 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 349 351 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 352 354 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
NF-kappaB-regulated genes are involved in invasiveness, proliferation, angiogenesis, lymphangiogenesis and inflammation, and are therefore good candidates for explaining the particular characteristics of IBC [14,15]. Increasing evidence suggests that NF-kappaB-associated pathways are dysregulated in numerous malignancies, including breast cancer [16-20].
###end p 14
###begin p 15
###xml 130 132 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 133 135 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 136 138 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 268 273 <span type="species:ncbi:9606">human</span>
To confirm the role of NF-kappaB target genes in IBC tumorigenesis, we focused on 60 key genes involved in the NF-kappaB pathway [14,15,21]. We chose real-time quantitative RT-PCR to measure the expression levels of these 60 genes in a well-characterized series of 35 human IBC samples relative to a series of 22 non IBC tumors and 24 distant metastases of breast cancer ("poor prognosis" controls).
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and samples
###end title 17
###begin p 18
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 64 69 <span type="species:ncbi:9606">women</span>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
###xml 754 762 <span type="species:ncbi:9606">patients</span>
The IBC samples were surgical biopsy specimens obtained from 35 women treated at Saint-Louis Hospital, Paris, France, between 1988 and 1995. IBC was diagnosed on the basis of rapidly progressive signs such as localized or generalized induration, redness and edema of the breast (stage T4d in the 1977 UICC classification). The 35 IBCs were also classified using a staging system named 'Poussee Evolutive' (PEV) developed by Gustave-Roussy investigators in an attempt to refine prognostication in IBC. This staging system takes into consideration aggressiveness of the tumor and signs of inflammation [22]. Using this system, both PEV2 and PEV3 are consistent with IBC. In 13 patients the entire affected breast was inflammatory (stage PEV3), while in 22 patients the inflammation was localized (stage PEV2).
###end p 18
###begin p 19
###xml 126 134 <span type="species:ncbi:9606">patients</span>
###xml 261 269 <span type="species:ncbi:9606">patients</span>
###xml 317 324 <span type="species:ncbi:9606">patient</span>
All biopsies were performed before treatment, and infiltrating carcinoma was documented histologically in every case. All the patients underwent first-line high-dose anthracycline-based chemotherapy followed by local treatment. At the time of this analysis, 26 patients had relapsed and 9 remained disease-free. Each patient gave written informed consent. The Local Ethical Committee approved this study.
###end p 19
###begin p 20
As "non IBC" controls, we used specimens of 22 non inflammatory locally advanced breast cancers (LABCs), of which 6 were stage IIb and 16 were non inflammatory stage III. These 22 non IBC controls were all high-grade invasive ductal carcinomas (Scarff-Bloom-Richardson histopathological grade III). The mRNA levels of the 60 genes in IBCs were expressed relative to those in non IBCs.
###end p 20
###begin p 21
As "poor prognosis breast tumor controls" we used biopsies of 24 distant metastases (10 liver, 7 lung, 4 skin, 2 ovary and 1 stomach) of non IBCs distinct from the 22 "non IBC" controls.
###end p 21
###begin p 22
The tumor samples were flash-frozen in liquid nitrogen and stored at -80degreesC until RNA extraction. Only tumor samples containing more than 70% of tumor cells were used.
###end p 22
###begin title 23
Real-time RT-PCR
###end title 23
###begin p 24
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
The theoretical and practical aspects of real-time quantitative RT-PCR using the ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems) have been described in detail elsewhere [13].
###end p 24
###begin p 25
###xml 298 302 298 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP </italic>
###xml 427 433 427 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0 </italic>
###xml 580 584 580 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP </italic>
###xml 588 593 588 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLPO</italic>
###xml 621 625 621 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP </italic>
###xml 730 734 730 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP </italic>
###xml 920 926 920 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0 </italic>
###xml 982 985 982 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP</italic>
###xml 1183 1187 1183 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP </italic>
###xml 1191 1196 1191 1196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLPO</italic>
###xml 1217 1223 1217 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">target</italic>
###xml 1246 1253 1246 1253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">target </italic>
###xml 1256 1271 1256 1267 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#916;Ct sample </sup>
###xml 1430 1445 1422 1437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP (or RPLP0) </italic>
###xml 460 465 <span type="species:ncbi:9606">human</span>
The precise amount of total RNA added to each reaction mix (based on optical density) and its quality (i.e. lack of extensive degradation) are both difficult to assess. We therefore also quantified transcripts of two endogenous RNA control genes involved in two cellular metabolic pathways, namely TBP (Genbank accession ), which encodes the TATA box-binding protein (a component of the DNA-binding protein complex TFIID), and RPLP0 (NM_001002), which encodes human acidic ribosomal phosphoprotein P0. The results for each sample were normalized on the basis of the corresponding TBP (or RPLPO) mRNA content. We selected TBP as an endogenous control because its transcripts are moderately abundant, and because there are no known TBP retropseudogenes. [Retropseudogenes lead to co-amplification of contaminating genomic DNA and thus interfere with RT-PCR, despite the use of primers in separate exons.] We also selected RPLP0 because its transcripts are more abundant than those of TBP, and because this gene (better known as 36B4) is widely used as an endogenous control for northern blot analysis. Results, expressed as N-fold differences in target gene expression relative to the TBP (or RPLPO) gene, and termed "Ntarget", were determined as Ntarget = 2DeltaCt sample where the DeltaCt (cycle threshold) value of the sample was determined by subtracting the average Ct value of the target gene from the average Ct value of the TBP (or RPLP0) gene.
###end p 25
###begin p 26
###xml 5 12 5 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">target </italic>
###xml 100 107 100 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">target </italic>
The Ntarget values of the samples were subsequently normalized such that the median of the non IBC Ntarget values was 1.
###end p 26
###begin p 27
###xml 12 15 12 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP</italic>
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0 </italic>
###xml 58 59 58 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Primers for TBP, RPLP0 and the 60 target genes (see Table 1) were chosen with the assistance of the Oligo 5.0 computer program (National Biosciences, Plymouth, MN).
###end p 27
###begin p 28
List of the 60 selected genes
###end p 28
###begin p 29
We searched the dbEST and nr databases to confirm the total gene specificity of the nucleotide sequences chosen as primers, and the absence of single nucleotide polymorphisms. In particular, the primer pairs were selected to be unique relative to the sequences of closely related family member genes or of the corresponding retropseudogenes. To avoid amplification of contaminating genomic DNA, one of the two primers was placed at the junction between two exons, if possible. In general, amplicons were between 60 and 120 nucleotides long. Gel electrophoresis was used to verify the specificity of PCR amplicons.
###end p 29
###begin p 30
For each primer pair we performed no-template control (NTC) and no-reverse-transcriptase control (RT-negative) assays, which produced negligible signals (usually > 40 in Ct values), suggesting that primer-dimer formation and genomic DNA contamination effects were negligible.
###end p 30
###begin p 31
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
The RNA extraction, cDNA synthesis and PCR conditions have been described in detail elsewhere [13].
###end p 31
###begin title 32
Statistical analysis
###end title 32
###begin p 33
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
As the mRNA levels did not fit a Gaussian distribution, (a) the mRNA levels in each subgroup of samples were characterized by their median and range rather than their mean and coefficient of variation, and (b) relationships between the molecular markers and clinical and histological parameters were tested with the non parametric Mann-Whitney U test [23].
###end p 33
###begin p 34
###xml 58 60 58 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
Hierarchical clustering was done with GeneANOVA software [24].
###end p 34
###begin title 35
Results
###end title 35
###begin title 36
###xml 54 67 50 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1/ER&#945; </italic>
###xml 71 77 63 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MKI67 </italic>
mRNA expression of the 60 NF-kappaB-associated genes, ESR1/ERalpha and MKI67 in 35 IBCs and 22 non IBCs
###end title 36
###begin p 37
###xml 267 271 267 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL1A</italic>
###xml 273 276 273 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL6</italic>
###xml 278 283 278 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL12B</italic>
###xml 289 293 289 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF2</italic>
The expression level of the 60 genes was determined individually in 35 IBCs and 22 non IBCs. Very low levels of target gene mRNA, that were detectable but not reliably quantifiable by real-time quantitative RT-PCR (Ct > 32), were observed for 4 (7%) of the 60 genes (IL1A, IL6, IL12B, and CSF2).
###end p 37
###begin p 38
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 148 158 148 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BIRC4/XIAP</italic>
Thirty-five of the remaining 56 genes were significantly upregulated in the 35 IBCs relative to the 22 non IBCs (p < 0.05; Table 2). Only one gene, BIRC4/XIAP, was significantly down-regulated in the IBCs.
###end p 38
###begin p 39
List of the significantly dysregulated NF-KB-related genes in IBCs relative to non IBCs
###end p 39
###begin p 40
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
a Median (range) of gene mRNA levels
###end p 40
###begin p 41
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 27 30 27 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
b Mann-Whitney U test: IBC vs non IBC
###end p 41
###begin p 42
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">C </sup>
###xml 34 37 34 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs </italic>
C Mann-Whitney U test: Metastases vs non IBC
###end p 42
###begin p 43
###xml 51 56 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKB1</italic>
###xml 58 62 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RELA</italic>
###xml 64 69 60 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBKG</italic>
###xml 71 77 67 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKBIB</italic>
###xml 79 84 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NFKB2</italic>
###xml 86 89 82 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">REL</italic>
###xml 91 95 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHUK</italic>
###xml 150 155 142 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCL1L</italic>
###xml 157 168 149 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFAIP3/A20</italic>
###xml 170 177 162 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GADD45B</italic>
###xml 179 184 171 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FASLG</italic>
###xml 186 191 178 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCL1S</italic>
###xml 193 198 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IER3L</italic>
###xml 200 217 192 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFRSF10B/TRAILR2</italic>
###xml 237 241 229 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD40</italic>
###xml 243 247 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD48</italic>
###xml 249 262 241 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFSF11/RANKL</italic>
###xml 264 278 256 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFRSF11A/RANK</italic>
###xml 280 290 272 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCL2/MCP-1</italic>
###xml 292 298 284 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD40LG</italic>
###xml 300 304 292 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL15</italic>
###xml 306 310 298 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GBP1</italic>
###xml 328 333 320 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 335 340 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND3</italic>
###xml 342 347 334 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF1R</italic>
###xml 349 353 341 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF1</italic>
###xml 355 359 347 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD2</italic>
###xml 381 387 373 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL12</italic>
###xml 389 393 381 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SELE</italic>
###xml 395 398 387 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNC</italic>
###xml 400 405 392 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VCAM1</italic>
###xml 407 412 399 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ICAM1</italic>
###xml 414 422 406 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLAU/UPA</italic>
###xml 441 451 433 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGS2/COX2</italic>
###xml 453 463 445 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL1/GRO1</italic>
The 35 upregulated genes included NF-kappaB genes (NFKB1, RELA, IKBKG, NFKBIB, NFKB2, REL, CHUK) and NF-kappaB-regulated genes involved in apoptosis (MCL1L, TNFAIP3/A20, GADD45B, FASLG, MCL1S, IER3L, TNFRSF10B/TRAILR2), immune response (CD40, CD48, TNFSF11/RANKL, TNFRSF11A/RANK, CCL2/MCP-1, CD40LG, IL15, GBP1), proliferation (CCND2, CCND3, CSF1R, CSF1, SOD2), tumor progression (CXCL12, SELE, TNC, VCAM1, ICAM1, PLAU/UPA) or angiogenesis (PTGS2/COX2, CXCL1/GRO1).
###end p 43
###begin p 44
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 140 151 140 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGS2/COX2 </italic>
###xml 155 165 155 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL1/GRO1</italic>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 415 420 415 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF1R</italic>
###xml 422 426 422 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD48</italic>
###xml 428 433 428 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IKBKG</italic>
###xml 435 441 435 441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD40LG</italic>
###xml 443 447 443 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CSF1</italic>
###xml 453 456 453 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">REL</italic>
###xml 537 538 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
The expression of most of the 35 genes that were upregulated in IBCs was similar in the metastases and the 22 non IBCs (Table 2). Only two (PTGS2/COX2 and CXCL1/GRO1) of these 35 genes were also upregulated in the metastases relative to the 22 non IBCs (Table 2). It is noteworthy that these two genes correspond to the two angiogenesis genes that were significantly upregulated in the 35 IBCs. Finally, six genes (CSF1R, CD48, IKBKG, CD40LG, CSF1, and REL) were slightly down-regulated in the metastases relative to the non IBCs (Table 2).
###end p 44
###begin p 45
###xml 82 95 82 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1/ER&#945; </italic>
###xml 108 114 104 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MKI67 </italic>
###xml 181 194 177 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ESR1/ER&#945; </italic>
###xml 198 204 190 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MKI67 </italic>
###xml 367 368 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
In the same set of 35 IBCs and 22 non IBCs we also examined the expression of the ESR1/ERalpha gene and the MKI67 gene, the latter encoding the proliferation-related antigen Ki-67. ESR1/ERalpha and MKI67 expression was similar in the IBCs and non IBCs, indicating that NF-kB gene upregulation in IBCs occurs in a proliferation- and ERalpha-independent fashion (Table 2).
###end p 45
###begin p 46
###xml 34 35 34 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 64 85 64 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Materials and Methods</italic>
###xml 156 159 156 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TBP</italic>
###xml 290 296 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPLP0 </italic>
The mRNA levels reported in Table 2 (calculated as described in Materials and Methods) show the abundance of the target relative to the endogenous control (TBP), used to normalize the starting amount and quality of total RNA. Similar results were obtained with a second endogenous control, RPLP0 (data not shown).
###end p 46
###begin title 47
Identification of a gene expression signature discriminating IBCs from non IBCs
###end title 47
###begin p 48
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Hierarchical clustering analysis was used to group the 28 most strongly upregulated genes (p < 0.01) on the basis of similarity in the pattern with which their expression varied over the 57 tumors (IBCs and non IBCs). The 28 genes were thus divided into six groups (Figure 1).
###end p 48
###begin p 49
###xml 0 166 0 166 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Dendrogram of the 28 most strongly upregulated genes (p &lt; 0.01) constructed using hierarchical clustering, according to the gene profiling of the 57 IBCs and non IBCs</bold>
###xml 317 328 317 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFAIP3/A20</italic>
###xml 330 334 330 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SELE</italic>
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COX2</italic>
###xml 342 348 342 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL12</italic>
###xml 350 355 350 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND3</italic>
###xml 357 362 357 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IER3L</italic>
###xml 365 366 365 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
Dendrogram of the 28 most strongly upregulated genes (p < 0.01) constructed using hierarchical clustering, according to the gene profiling of the 57 IBCs and non IBCs. The 28 genes were categorized into 6 groups. The 6 most strongly upregulated genes (named master gene) within each group are indicated on the right (TNFAIP3/A20, SELE, COX2, CXCL12, CCND3, IER3L). a: Mann-Whitney U Test (see table 2).
###end p 49
###begin p 50
###xml 44 55 44 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFAIP3/A20</italic>
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SELE</italic>
###xml 63 67 63 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COX2</italic>
###xml 69 75 69 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL12</italic>
###xml 77 82 77 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND3</italic>
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IER3L</italic>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
We then selected six "master genes", namely TNFAIP3/A20, SELE, COX2, CXCL12, CCND3, and IER3L, corresponding to the most discriminatory genes in each group (based on the p values, cf. Table 2). Hierarchical clustering of the 35 IBC and 22 non IBC samples, based on the expression of these six master genes (see dendrogram in Figure 2) identified two groups of tumor samples, with 96.3% (26/27) of IBCs clustered in one group and 30% (9/30) in the second group (p = 0.0000003). The signature correctly classified 26 of 35 IBCs (74% sensitivity) and 21 of 22 non IBCs (95% specificity).
###end p 50
###begin p 51
###xml 142 153 142 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFAIP3/A20</italic>
###xml 155 159 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SELE</italic>
###xml 161 165 161 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COX2</italic>
###xml 167 173 167 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL12</italic>
###xml 175 180 175 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND3</italic>
###xml 186 191 186 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IER3L</italic>
Dendrogram of the 35 IBCs and the 22 non IBC samples, constructed using hierarchical clustering, according to the expression of 6 genes, i.e. TNFAIP3/A20, SELE, COX2, CXCL12, CCND3, and IER3L. This analysis revealed two groups of tumors with 96,3% (26/27) of IBCs clustered in one group and 30% (9/30) in the second group.
###end p 51
###begin title 52
mRNA expression of the 56 candidate genes according to IBC relapse status
###end title 52
###begin p 53
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VEGF </italic>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL8 </italic>
###xml 27 35 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
Twenty-six (74%) of the 35 patients with IBC relapsed, a proportion in keeping with published data [25]. Comparison of the median mRNA levels of the 56 candidate genes between patients who relapsed (n = 26) and patients who did not relapse (n = 9) identified two genes -VEGF (p = 0.048) and IL8 (p = 0.042)- with lower expression in patients who relapsed.
###end p 53
###begin p 54
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 104 108 104 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EREG</italic>
###xml 114 118 114 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SHH </italic>
###xml 232 234 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
In the same series of IBCs, we had previously identified a three-gene expression profile based on MYCN, EREG, and SHH (genes not involved in the NF-kappaB pathway) which discriminated cases with poor, intermediate and good outcome [13].
###end p 54
###begin p 55
###xml 128 132 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 134 138 134 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EREG</italic>
###xml 144 147 144 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SHH</italic>
###xml 184 189 184 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VEGF </italic>
###xml 193 196 193 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL8</italic>
###xml 297 298 297 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
###xml 315 323 <span type="species:ncbi:9606">patients</span>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
Hierarchical clustering analysis of the 35 IBCs based on a five-gene signature including the three previously identified genes (MYCN, EREG, and SHH) and the two genes identified here (VEGF and IL8) subdivided the patients into three groups with significantly different outcomes (p = 0.009; Figure 3): two groups of patients had very poor outcomes (respectively 100% and 88.9% relapsed), whereas 50% of the patients in the third group were free of relapse at the time of this analysis
###end p 55
###begin p 56
###xml 66 73 66 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">circled</italic>
###xml 128 151 128 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN/EREG/SHH/IL8/VEGF </italic>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
Dendrogram of 26 IBCs who relapsed (R) and 9 who did not relapse (circled) constructed by hierarchical clustering, according to MYCN/EREG/SHH/IL8/VEGF expression. The percentage of patients who relapsed are indicated on the right.
###end p 56
###begin title 57
Discussion
###end title 57
###begin p 58
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 281 283 281 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 882 884 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 885 887 885 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
IBC is a poorly understood disease with a dismal prognosis. Diagnosis is based on variously appreciated clinical signs, and prognostic factors are sorely needed. Despite multimodality treatments, the overall outcome of IBC is almost as grim as that of metastatic breast cancer [25,26]. Identification of a molecular signature might help to improve the diagnosis, as well as the prognostication and targeted therapy of IBC. The specific molecular alterations underlying IBC are largely unknown, owing to the rarity of the disease together with diagnostic uncertainties and the small size of diagnostic samples, which may have hindered past molecular studies. Moreover, previous molecular studies often grouped IBCs together with non inflammatory LABCs, whereas IBC was recently shown to be distinct from other forms of LABC, probably with different underlying molecular alterations [27,28].
###end p 58
###begin p 59
###xml 266 268 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 269 271 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 383 384 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 385 387 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
Two major lines of evidence implicate NF-kappaB-associated pathways in IBC. First, NF-kappaB target genes are involved in the principal processes that are dysregulated at the clinical and molecular level in IBC, such as inflammation, proliferation and invasiveness [14,15]. Second, recent DNA microarrays studies of IBC have shown abnormal expression of some NF-kappaB target genes [9,10].
###end p 59
###begin p 60
###xml 244 276 244 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COX2, CXCL1/GRO1, TNFSF11/RANKL </italic>
###xml 280 287 280 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD40LG </italic>
Real-time quantitative RT-PCR is complementary to cDNA microarray technology for tumor molecular profiling, being quantitative and also far more precise and reproducible. Moreover, RT-PCR is useful for analyzing weakly expressed genes, such as COX2, CXCL1/GRO1, TNFSF11/RANKL and CD40LG in the present study.
###end p 60
###begin p 61
###xml 240 245 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COX2 </italic>
###xml 249 254 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VEGF </italic>
###xml 255 257 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 435 437 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 438 440 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 441 443 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 521 522 509 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
By using RT-PCR to compare the mRNA levels of 538 cancer genes in the same series of IBCs and non IBCs, we previously showed the upregulation of genes that mainly encoded AP1 transcription factors, but also some NF-kappaB target genes like COX2 and VEGF [13]. As the list of NF-kappaB-associated genes of interest was very incomplete in this previous study, we thoroughly scrutinized the literature on NF-kappaB for the present study [14,15,21]. A set of 60 major NFKB-related genes was selected for this analysis (Table 1).
###end p 61
###begin p 62
###xml 369 371 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 463 465 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 579 584 567 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VCAM1</italic>
###xml 586 590 574 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5</italic>
###xml 592 596 580 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD2</italic>
###xml 598 602 586 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB</italic>
###xml 604 608 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IRF7</italic>
###xml 610 614 598 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GBP1</italic>
###xml 620 624 608 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD48</italic>
###xml 678 680 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 681 683 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 729 747 717 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VCAM1, CD48, GBP1 </italic>
###xml 751 756 739 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD2 </italic>
###xml 849 860 837 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCR5, IRF7 </italic>
###xml 864 869 852 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTSB </italic>
###xml 884 885 872 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
The very high proportion (58%) of upregulated NF-kappaB-associated genes in our series of IBC was not entirely unexpected, given the functional roles of these genes in invasiveness, angiogenesis, inflammation, cell proliferation and survival. In their DNA microarray study, van Laere et al also observed a noteworthy proportion of overexpressed NF-kappaB target genes [10]. More recently, the same authors confirmed the involvement of some of these genes in IBC [12]. In particular, they validated by quantitative real-time RT-PCR the overexpression of 7 NF-kappaB-target genes (VCAM1, CCR5, SOD2, CTSB, IRF7, GBP1, and CD48) previously detected by them using cDNA microarrays [10,12]. We tested these seven genes in our series; VCAM1, CD48, GBP1 and SOD2 also showed a moderately significant overexpression in IBC relative to the non IBCs, whereas CCR5, IRF7 and CTSB did not (Table 2).
###end p 62
###begin p 63
###xml 315 326 311 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTGS2/COX2 </italic>
###xml 330 340 326 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL1/GRO1</italic>
One very interesting finding here is that the gene expression profile of 24 distant breast metastases was quite different from that of the 35 IBCs, as all the NF-kappaB-associated genes were expressed at similar levels in the 24 metastatic samples and the 22 non IBCs (except for the two angiogenesis-related genes PTGS2/COX2 and CXCL1/GRO1). This further supports a strong specific link between NF-kappaB gene activation and the IBC phenotype.
###end p 63
###begin p 64
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL12</italic>
###xml 8 12 8 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COX2</italic>
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND2</italic>
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCL1L</italic>
###xml 28 39 28 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFAIP3/A20</italic>
###xml 45 53 45 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GADD45B </italic>
###xml 116 123 116 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL12 </italic>
###xml 140 146 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCR4 </italic>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 600 605 600 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COX2 </italic>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 752 757 752 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COX2 </italic>
###xml 937 938 933 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1007 1012 1003 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCL1L</italic>
###xml 1014 1025 1010 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFAIP3/A20</italic>
###xml 1031 1038 1027 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GADD45B</italic>
###xml 1080 1088 1076 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GADD45B </italic>
###xml 1115 1117 1111 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1277 1279 1269 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
CXCL12, COX2, CCND2, MCL1L, TNFAIP3/A20, and GADD45B were the most strongly deregulated genes in our series of IBC. CXCL12 and its receptor CXCR4 play major roles in embryogenesis, homeostasis and inflammation. They are also key regulators of carcinogenesis, acting through a wide range of mechanisms such as increased survival and proliferation of cancer cells, angiogenesis and chemoinvasion [29]. Many studies have now validated the concept that this receptor-ligand pair strongly influences metastasis, in particular by directing the migration of cancer cells to sites of metastasis. The role of COX2 in mammary oncogenesis is also well established, and clinical trials of COX2 inhibitors like celecoxib are ongoing in breast cancer [30]. However, COX2 was also upregulated in the breast-cancer metastases and was thus not specifically dysregulated in IBC, contrary to most of the other NF-kappaB-associated genes tested here (Table 2). We observed an overexpression of three anti-apoptotic genes: i.e. MCL1L, TNFAIP3/A20, and GADD45B. Van Laere et al. also observed elevated GADD45B expression in IBC samples [10]. The activation of NF-kappaB-dependent anti-apoptotic genes may promote IBC tumorigenesis, as it has been shown in other inflammation-associated tumor types [31]. However, what matters in IBC is probably not the overexpression of a particular NF-kappaB-associated gene but rather the activation of the entire NF-kappaB pathway.
###end p 64
###begin p 65
###xml 394 405 394 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFAIP3/A20</italic>
###xml 407 411 407 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SELE</italic>
###xml 413 417 413 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COX2</italic>
###xml 419 425 419 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL12</italic>
###xml 427 432 427 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND3</italic>
###xml 434 439 434 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IER3L</italic>
###xml 816 817 816 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 831 837 831 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCND3 </italic>
###xml 841 845 841 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SELE</italic>
###xml 968 979 968 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNFAIP3/A20</italic>
###xml 981 985 981 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COX2</italic>
###xml 987 993 987 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CXCL12</italic>
###xml 999 1004 999 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IER3L</italic>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 592 599 <span type="species:ncbi:9606">patient</span>
We think that one of the best ways to identify specific molecular alterations in IBC is to use "stage-matched" non inflammatory breast tumors as controls, and to strictly select patients with IBC. This approach can point out genes that are specifically associated with the IBC phenotype rather than with a poor prognosis in general. Applying these criteria, we identified a six-gene signature (TNFAIP3/A20, SELE, COX2, CXCL12, CCND3, IER3L) discriminating IBC from non IBC. However, nine IBCs were misclassified as non IBCs, even though they did not differ from the other 26 IBCs in terms of patient age, histological grade, hormone receptor status, PEV classification or prognosis (data not shown). The 6-gene signature was tested on an independent series of 37 IBCs and 44 non IBCs studied using cDNA microarrays [9]. Two genes (CCND3 and SELE) significantly discriminated the 37 IBC from the 44 non IBCs (p = 0,01; Bertucci F, personal data). The other four genes (TNFAIP3/A20, COX2, CXCL12, and IER3L) were not expressed at significant levels (> 2 x background signal in at least 50% of all tumor samples). Unfortunately, we could not test the signature at the protein level because no more paired paraffin-embedded tumor samples were available for immunohistochemistry (IHC) analysis. It will be important to perform the IHC on an independent prospective series of IBC samples.
###end p 65
###begin p 66
###xml 323 325 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
Contrary to some DNA anomalies that we have previously observed in IBC by means of allelic imbalance analysis, we found no significant difference here in NF-kappaB-associated gene expression levels between PEV2 tumors (localized inflammation) and PEV3 tumors (extensive inflammation and poorer prognosis than PEV2 tumors) [32]. In particular, our previous study showed that 17q21 deletion was more frequent in PEV3 tumors. However, none of the genes found to be upregulated in the present study is located in this region. Finally, it should be borne in mind that several genes may be altered in all IBCs while others are specifically altered in certain IBC subtypes.
###end p 66
###begin p 67
###xml 151 156 147 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VEGF </italic>
###xml 160 164 156 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL8 </italic>
###xml 309 313 305 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VEGF</italic>
###xml 315 319 311 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL8 </italic>
###xml 340 344 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MYCN</italic>
###xml 346 349 342 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SHH</italic>
###xml 355 359 351 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EREG</italic>
###xml 445 447 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 547 548 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
We also examined the prognostic significance of NF-kappaB-associated genes in IBC. Although the statistical significance was weak, we found that lower VEGF and IL8 expression was associated with relapse. This is surprising, as both genes promote angiogenesis. Furthermore, a five-gene expression profile with VEGF, IL8 and the three genes (MYCN, SHH, and EREG) that we previously showed to be associated with outcome in the same series of IBCs [13] clearly delineated two subgroups of IBC with high (near 100%) and low (50%) relapse rates (Figure 3).
###end p 67
###begin title 68
Conclusion
###end title 68
###begin p 69
###xml 418 420 402 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 421 423 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 545 547 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 548 550 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
These results demonstrate that the NF-kappaB pathway plays a major role in IBC. Activation of NF-kappaB-associated genes appears to contribute to the IBC phenotype and may prove to be of prognostic significance. Furthermore, upregulated NF-kappaB-related genes might serve as novel therapeutic targets in IBC. It is noteworthy that several NF-kappaB inhibitors are known to have antitumoral activity in breast cancer [33,34] and that one has been shown to halt the growth of IBC xenografts, either alone or in combination with an anthracycline [35,36].
###end p 69
###begin title 70
Competing interests
###end title 70
###begin p 71
The author(s) declare that they have no competing interests.
###end p 71
###begin title 72
Authors' contributions
###end title 72
###begin p 73
###xml 155 163 <span type="species:ncbi:9606">patients</span>
FL helped design the study and analyze data, and wrote the manuscript. SV and CA did RNA extraction, cDNA synthesis and QRT-PCR. ME and MM participated in patients' selection and treatment. RL collected specimens and helped design the study. IB designed the study and analyzed data. All authors read and approved the final manuscript.
###end p 73
###begin title 74
Pre-publication history
###end title 74
###begin p 75
The pre-publication history for this paper can be accessed here:
###end p 75
###begin p 76

###end p 76
###begin title 77
Acknowledgements
###end title 77
###begin p 78
###xml 27 100 27 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Comite Regional des Hauts-de-Seine de la Ligue Nationale Contre le Cancer</italic>
This work was supported by Comite Regional des Hauts-de-Seine de la Ligue Nationale Contre le Cancer.
###end p 78
###begin article-title 79
Inflammatory breast cancer: a review
###end article-title 79
###begin article-title 80
###xml 89 94 <span type="species:ncbi:9606">human</span>
Oestrogen and progesterone cytosolic receptors in clinically inflammatory tumours of the human breast
###end article-title 80
###begin article-title 81
Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance
###end article-title 81
###begin article-title 82
Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease
###end article-title 82
###begin article-title 83
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer
###end article-title 83
###begin article-title 84
Update on inflammatory breast cancer
###end article-title 84
###begin article-title 85
Repeated observation of breast tumor subtypes in independent gene expression data sets
###end article-title 85
###begin article-title 86
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
###end article-title 86
###begin article-title 87
Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy
###end article-title 87
###begin article-title 88
Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis
###end article-title 88
###begin article-title 89
Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype
###end article-title 89
###begin article-title 90
Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding
###end article-title 90
###begin article-title 91
Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature
###end article-title 91
###begin article-title 92
Nuclear factor-kappaB the enemy within
###end article-title 92
###begin article-title 93
NF-kappaB in cancer: from innocent bystander to major culprit
###end article-title 93
###begin article-title 94
###xml 25 30 <span type="species:ncbi:9606">human</span>
NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis
###end article-title 94
###begin article-title 95
NF-kappaB in mammary gland development and breast cancer
###end article-title 95
###begin article-title 96
###xml 47 52 <span type="species:ncbi:9606">human</span>
Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3
###end article-title 96
###begin article-title 97
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression
###end article-title 97
###begin article-title 98
Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth
###end article-title 98
###begin article-title 99
Nuclear factor-kappaB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer
###end article-title 99
###begin article-title 100
[Breast cancers in the evolutive phase]
###end article-title 100
###begin article-title 101
On a test of whether one or two random variables is stochastically larger than the other
###end article-title 101
###begin article-title 102
GeneANOVA-gene expression analysis of variance
###end article-title 102
###begin article-title 103
Update on the management of inflammatory breast cancer
###end article-title 103
###begin article-title 104
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Goals of treatment for patients with metastatic breast cancer
###end article-title 104
###begin article-title 105
Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?
###end article-title 105
###begin article-title 106
Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute
###end article-title 106
###begin article-title 107
Functions of CXCL12 and CXCR4 in breast cancer
###end article-title 107
###begin article-title 108
###xml 90 95 <span type="species:ncbi:9606">human</span>
Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer
###end article-title 108
###begin article-title 109
NF-kappaB functions as a tumour promoter in inflammation-associated cancer
###end article-title 109
###begin article-title 110
Two prognostic groups of inflammatory breast cancer have distinct genotypes
###end article-title 110
###begin article-title 111
Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo
###end article-title 111
###begin article-title 112
###xml 45 50 <span type="species:ncbi:9606">human</span>
A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition
###end article-title 112
###begin article-title 113
Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma
###end article-title 113
###begin article-title 114
Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade
###end article-title 114

